These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

532 related items for PubMed ID: 18405247

  • 1. Impact of sirolimus treatment in kidney allograft recipients with prolonged cold ischemia times: 5-year outcomes.
    Boratynska M, Banasik M, Patrzalek D, Klinger M.
    Exp Clin Transplant; 2008 Mar; 6(1):59-66. PubMed ID: 18405247
    [Abstract] [Full Text] [Related]

  • 2. Sirolimus delays recovery from posttransplant renal failure in kidney graft recipients.
    Boratyńska M, Banasik M, Patrzalek D, Szyber P, Klinger M.
    Transplant Proc; 2005 Mar; 37(2):839-42. PubMed ID: 15848550
    [Abstract] [Full Text] [Related]

  • 3. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study.
    Oberbauer R, Kreis H, Johnson RW, Mota A, Claesson K, Ruiz JC, Wilczek H, Jamieson N, Henriques AC, Paczek L, Chapman J, Burke JT, Rapamune Maintenance Regimen Study Group.
    Transplantation; 2003 Jul 27; 76(2):364-70. PubMed ID: 12883194
    [Abstract] [Full Text] [Related]

  • 4. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 5. The combination of sirolimus and cyclosporine does not delay initial renal graft function recovery.
    Hsu HJ, Tian YC, Chen YC, Lai BC, Fang JT, Yang CW, Wu MS.
    Ren Fail; 2008 Jan 27; 30(3):303-6. PubMed ID: 18350450
    [Abstract] [Full Text] [Related]

  • 6. Tubular toxicity in sirolimus- and cyclosporine-based transplant immunosuppression strategies: an ancillary study from a randomized controlled trial.
    Franz S, Regeniter A, Hopfer H, Mihatsch M, Dickenmann M.
    Am J Kidney Dis; 2010 Feb 27; 55(2):335-43. PubMed ID: 19926370
    [Abstract] [Full Text] [Related]

  • 7. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients.
    Baboolal K.
    Transplantation; 2003 Apr 27; 75(8):1404-8. PubMed ID: 12717239
    [Abstract] [Full Text] [Related]

  • 8. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
    Bemelman FJ, de Maar EF, Press RR, van Kan HJ, ten Berge IJ, Homan van der Heide JJ, de Fijter HW.
    Transplantation; 2009 Aug 15; 88(3):421-8. PubMed ID: 19667948
    [Abstract] [Full Text] [Related]

  • 9. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus.
    Albano L, Berthoux F, Moal MC, Rostaing L, Legendre C, Genin R, Toupance O, Moulin B, Merville P, Rerolle JP, Bayle F, Westeel PF, Glotz D, Kossari N, Lefrançois N, Charpentier B, Blanc AS, Di Giambattista F, Dantal J, RAD A2420 Study Group.
    Transplantation; 2009 Jul 15; 88(1):69-76. PubMed ID: 19584683
    [Abstract] [Full Text] [Related]

  • 10. Sirolimus does not increase the risk for postoperative thromboembolic events among renal transplant recipients.
    Langer RM, Kahan BD.
    Transplantation; 2003 Jul 27; 76(2):318-23. PubMed ID: 12883185
    [Abstract] [Full Text] [Related]

  • 11. Steroid and azathioprine versus steroid, cyclosporine, and azathioprine therapies in primary haplo-identical living donor kidney transplantation: twenty-year experience.
    Gheith OA, Bakr MA, Fouda MA, Shokeir AA, Bayoumy A, Sobh M, Ghoneim M.
    Iran J Kidney Dis; 2008 Jan 27; 2(1):34-9. PubMed ID: 19367007
    [Abstract] [Full Text] [Related]

  • 12. Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients.
    Stallone G, Di Paolo S, Schena A, Infante B, Grandaliano G, Battaglia M, Gesualdo L, Schena FP.
    Transplantation; 2003 Apr 15; 75(7):998-1003. PubMed ID: 12698087
    [Abstract] [Full Text] [Related]

  • 13. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A, Nart A, Taşli FA, Postaci H, Aykas A, Doğan M, Sahin T.
    Nephrology (Carlton); 2008 Feb 15; 13(1):80-6. PubMed ID: 18199109
    [Abstract] [Full Text] [Related]

  • 14. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 15. Cold ischemia is a major determinant of acute rejection and renal graft survival in the modern era of immunosuppression.
    Mikhalski D, Wissing KM, Ghisdal L, Broeders N, Touly M, Hoang AD, Loi P, Mboti F, Donckier V, Vereerstraeten P, Abramowicz D.
    Transplantation; 2008 Apr 15; 85(7 Suppl):S3-9. PubMed ID: 18401260
    [Abstract] [Full Text] [Related]

  • 16. Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients.
    Boratyńska M, Banasik M, Watorek E, Falkiewicz K, Patrzałek D, Szyber P, Klinger M.
    Transplant Proc; 2006 Apr 15; 38(1):101-4. PubMed ID: 16504675
    [Abstract] [Full Text] [Related]

  • 17. Sirolimus delays recovery of rat kidney transplants after ischemia-reperfusion injury.
    Fuller TF, Freise CE, Serkova N, Niemann CU, Olson JL, Feng S.
    Transplantation; 2003 Dec 15; 76(11):1594-9. PubMed ID: 14702530
    [Abstract] [Full Text] [Related]

  • 18. Long-term kidney transplant outcomes in patients receiving oil-based or microemulsion formulations of cyclosporine.
    Medina-Pestana JO, Felipe CR, Park SI, Machado PG, Garcia R, Spinelli G, Silva LA, Santos CF, Tedesco-Silva H.
    Transplant Proc; 2004 Mar 15; 36(2 Suppl):74S-79S. PubMed ID: 15041311
    [Abstract] [Full Text] [Related]

  • 19. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S, He X, Yang L, Ma Y, Zhu X, Ju W, Huang J.
    Exp Clin Transplant; 2008 Jun 15; 6(2):113-7. PubMed ID: 18816237
    [Abstract] [Full Text] [Related]

  • 20. The efficacy and safety of cyclosporine reduction in de novo renal allograft patients receiving sirolimus and corticosteroids: results from an open-label comparative study.
    Mühlbacher F, Neumayer HH, del Castillo D, Stefoni S, Zygmunt AJ, Budde K, European Rapamune Cyclosporine Minimization Study Group.
    Transpl Int; 2014 Feb 15; 27(2):176-86. PubMed ID: 24266855
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.